A Monthly Test for Diabetes
The Epinex G1A Test: The Key to Better Diabetes Control
*
* This Product is under development and intended for information and evaluation purposes only. It is NOT APPROVED by the FDA
Epinex Diagnostics: Developing Innovative Tests for Underserved Markets
Epinex is founded on the principle of applying expert scientific knowledge and proprietary technology for the benefit of users and the healthcare system. We are dedicated to advancing the technology of rapid diagnostics in order to provide easy access to critical diagnostic information at low cost. Our goal is to enhance patients' quality of life with diagnostic tests at the office, point of care, and over the counter to reduce costs, alleviate patient anxiety, enable earlier therapeutic intervention, and improve patient outcome.
EPINEX PLATFORM TECHNOLOGY
Epinex product research has developed a proprietary platform for rapid tests that exploits existing technology of immunoassay strips and biosensors to create unique quantitative diagnostic tests.
Download Am I Diabetic App
-
Shareholder Conference Call on June 10,2021 @4PM PT (see email or call the office for details)
-
Epinex's Research on GA and Inflammation gets published by Springer Nature. 2017
-
Epinex's Scientific Advisory Board, Alan Carter Presents at ADA 2017
-
Chinese Patent Publication- Rapid Test for Urine Albumin and Urea Creatinine
-
"Glycated albumin, HbA1c levels linked in impaired glucose tolerance"
-
Empower patients to self-manage chronic conditions
-
Improve doctor-patient communication
-
Improve patient outcome
-
Reduce healthcare costs
OUR TESTS HAVE THE POTENTIAL TO NEWS PATENTS
CORPORATE INFORMATION SERIES
Diabetes Prevention – Challenge and Opportunity
Towards a New Glycation
Index